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Angiogenesis is critical for growth and metastatic spread of solid
tumours (Folkman, 1990) and is mediated by a number of angio-
genic growth factors, of which vascular endothelial growth factor
(VEGF) is the most potent inducer neovasculature (reviewed in
Klagsbrun and Soker, 1993). The VEGF gene consists of eight
exons that give rise to four different isoforms of VEGF (121, 165,
189 and 206 amino acids) by alternative splicing (Tischer et al,
1991). In both normal and transformed cells, VEGF165 appears to
be the most abundant gene product (Ferrara and Davis-Smyth,
1997). VEGF binds to specific high-affinity tyrosine kinase recep-
tors, termed Flt-1 and KDR, which mediate the VEGF response
(de Vries et al, 1992; Terman et al, 1992). Both receptors are
closely related and display 44% sequence homology, although Flt-
1 has highest affinity for recombinant human VEGF (rhVEGF) (de
Vries et al, 1992).
VEGF is produced by a number of tumours, including that of the
breast, and compared with other angiogenic factors, e.g. basic
fibroblast growth factor (bFGF), transforming growth factor (TGF)-
a and TGF-b, its production by breast tumours is significantly up-
regulated compared with adjacent normal tissue (Yoshiji et al,
1996). The importance of VEGF-induced neovascularization in
breast tumours may be seen from recent clinical studies which have
shown that the degree of tumour angiogenesis is an important prog-
nostic factor (Weidner et al, 1991; Toi et al, 1993). Further, VEGF is
one of the most important factors in promoting neovascularization
of breast tumours (Toi et al, 1996). The clinical prognostic value of
VEGF has been substantiated by two recent studies that demonstrate
that the level of VEGF165 is a strong, independent prognostic deter-
minant (Eppenberger et al, 1998; Linderholm et al, 1998).
Although VEGF is clearly an important factor in the angiogenic
process in breast cancer, there is scant information about the produc-
tion of bioactive VEGF or expression of VEGF receptors by specific
cell types in the breast. Therefore, the first aim of this study was to
determine the production of VEGF by primary cultures of breast
epithelial and stromal-enriched cells derived from human breast
tumours and its modulation by the cytokines interleukin (IL)-6 and
IL-8. These factors were selected as they have both previously been
shown to be up-regulated in breast cancer (Adams et al, 1991; Green
et al, 1997) and both induce angiogenesis (Koch et al, 1992; Cohen
et al, 1996). Secondly, we determined the in vitro expression of the
VEGF receptors, Flt-1 and KDR and assessed whether they may
mediate autocrine/paracrine proliferation.
METHODS
Cell culture
Surgically removed breast tumours (n = 10) were transported
immediately to the laboratory and dispersed overnight in collage-
nase III (Life Technologies, Paisley, UK) as previously described
(Speirs et al, 1996a). Individual epithelial and stromal prepara-
tions were isolated using a differential centrifugation method
followed by culture in selective media (Speirs et al, 1996b) and
were previously fully characterized by immunostaining, flow
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cytometry, gene expression and enzyme assay (Speirs et al, 1998).
Clinicopathological details of the tumours from which the cultures
were established are presented in Table 1. Six normal breast
samples from patients undergoing reduction mammoplasty were
dispersed enzymatically and cultured under the same conditions
as the tumour tissue. Ethical permission was granted for all the
studies performed.
RNA extraction and cDNA synthesis
Total RNA was extracted from pre-confluent cell cultures by the
addition of guanidinium isothiocyanate directly to the culture
vessel, ethanol precipitated and quantified by UV spectroscopy.
This was reverse transcribed into cDNA in a 20-ml reaction
containing 1 mg RNA, 2 mg oligo dT, 20 units of RNAsin (both
Pharmacia, St Albans, UK), 10 mM dithiothreitol (DTT), 0.1 mM
of each deoxynucleotide triphosphate (Boehringer Mannheim,
Lewes, UK), 10 units ml–1 of SuperScript RNase H– reverse tran-
scriptase (Life Technologies) and an appropriate volume of diethyl
pyrocarbonate-treated water. This was incubated for 1 h at 42°C,
heated to 99°C for 5 min, quick chilled on ice and stored at –20°C.
Polymerase chain reaction (PCR) was performed in a 50-ml
volume which contained the following: 2 units of DNA poly-
merase, 10 ´ PCR buffer (containing 1.5 mM magnesium chloride;
both Bioline, London, UK), 0.5 mg of each oligonucleotide primer
(Life Technologies), 200 mM each of dATP, dCTP, dTTP and
dGTP, 2 ml nascent cDNA and sterile distilled water to bring the
volume to 50 ml.
Semi-quantitative reverse transcription-PCR
Primer sequences for amplification of Flt-1 and the constitutively
expressed housekeeping gene glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), have been previously described
(de Vries et al, 1992; Green et al, 1996). PCR was performed as
follows: 2 ml of cDNA were amplified over 30 cycles with 2 U Bio
Taq polymerase, 10 ´ reaction buffer (both Bioline), 200 mM each
of dATP, dCTP, dTTP and dGTP (Boehringer Mannheim), 1.5 mM
megnesium chloride and distilled water to bring the volume up to
50 ml. For KDR, a nested PCR was performed as originally
described (Boocock et al, 1995), but with primer modifications.
cDNAs were amplified with KDR-specific primers 1 and 2 for 25
cycles (95°C 30 s, 60°C 30 s, 72°C 30 s). After amplification with
the first primer pair, 2 ml of product were reamplified in 50 ml of
fresh reaction mixture using the KDR-specific primers 3 and 4 for
a further 25 cycles (95°C 30 s, 62°C 30 s, 72°C 30 s). Reaction
buffer was identical to that used for Flt-1 and GAPDH. KDR
primers were as follows:
Primer 1: 5¢-ACG CTG ACA TGT ACG GTC TAT-3¢
Primer 2: 5¢-TTC CCA TTT GCT GGC ATC ATA-3¢
Primer 3: 5¢-CAT CAC ATC CAC TGG TAT TGG-3¢
Primer 4: 5¢-GCC AAG CTT GTA CCA TGT GAG-3¢
All PCRs were performed using an OmneGene thermal cycler
(Hybaid, London, UK). Substitution of cDNA with either sterile
distilled water or non-reverse transcribed RNA served as negative
controls; these were consistently negative. A total of 5 ml of each
PCR product were electrophoresed through a 2% agarose gel and
visualized by ethidium bromide staining under UV illumination.
To confirm the identity of the amplified fragments, representative
PCR products were incubated with 10% v/v restriction endo-
nuclease (Pvu II for Flt-1, Ava II for KDR; data not shown) which
cleaved the product into discrete fragments of predicted size.
Characterization of cell culture contaminants
To ensure our primary cultures did not contain endothelial contam-
inants which may have been the source of VEGF/VEGF receptors,
all epithelial and stromal cultures were characterized by reverse
transcription PCR (RT-PCR) for von Williebraad factor (VWF)
which is associated with endothelial cells. RT-PCR was performed
as described above using primers designed to detect fragment of
the VWF gene. Primer sequences were as follows:
Table 1 Production of VEGF and expression of VEGF receptors KDR and Flt-1 in cultures of primary epithelial and stromal cells derived from breast tumours
Sample VEGF GAPdH KDR Flt-1 Age Type Grade LN ER
(pg ml–1 mg–1 RNA)
BCa1 E 13 NA NA NA 63 Ductal II – +
S3 9N A N A N A
BCa2 E 38 + + – 56 Lobular I – +
S7 + + –
BCa3 E 70 NA NA NA 80 Ductal II – –
S5 9N A N A N A
BCa4 E 27 + + + 56 Ductal II + –
S7 5 + + +
BCa5 E 11 NA NA NA 72 Ductal II + +
S3 5N A N A N A
BCa6 E 51 NA NA NA 68 Ductal II + +
S6 7N A N A N A
BCa7 E 36 + + + 56 Ductal III – –
S9 2 + + +
BCa8 E 21 + + + 72 Ductal II + +
S7 + – +
BCa9 E NA + + + 55 Ductal II – –
SN A + – +
BCa10 E NA + + – 47 Ductal I – –
SN A + – +
LN, lymph node; ER, oestrogen receptor; BCa, breast cancer; E, epithelial culture; S, stromal culture; NA = not analysed.900 V Speirs and SL Atkin
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5¢-ACG GCT TGC ACC ATT CAG CT-3¢
5¢-CAG CCT CAC TTG CTG CAC TT-3¢
The thermal cycle consisted of a denaturation step of 94°C for
2 min, followed by 35 cycles of 94°C for 30 s, 57.5°C for 30 s,
72°C for 30 s, and was concluded with a final primer extension
step of 72°C for 5 min. As a positive control, cDNA obtained from
the endothelial cell line EAHY 926 was used. Non-reverse tran-
scribed RNA served as a negative control. Products were analysed
by agarose gel electrophoresis as described above.
Quantitative analysis of VEGF
Primary epithelial and stromal cultures were established in 12-well
plates and, when 70% confluent, incubated for 24 h with serum-
free medium. The resulting confluent medium (CM) was collected
and stored at –80°C until required. From the same cultures, RNA
was extracted as described above. CM was quantitatively analysed
for VEGF by enzyme-linked immunosorbent assay (ELISA)
(R&D Systems, Abingdon, UK). Prior to analysis, CM was
centrifuged to remove any particulate matter and assayed
according to the manufacturer’s instructions. The mean intra- and
inter-assay variances were 4.7% and 6.7%, respectively, with a
sensitivity of 5 pg ml–1 for VEGF165. No significant cross-
reactivity with a range of cytokines was observed (refer to
manufacturer’s instructions for complete list).
Effects of IL-6 and IL-8 on VEGF production by primary
epithelial and stromal cultures
Cultures were established from three tumours (BCa2, BCa3 and
BCa5) as described above and allowed to become semi-confluent
in 12-well plates. Medium was removed and replaced with fresh
serum-free medium containing 10 ng ml–1 IL-6 or IL-8 (both
Genzyme, West Malling, UK). Cultures were incubated with these
factors for a further 48 h, after which the medium was collected,
clarified by centrifugation and stored at –80°C until analysed for
VEGF by ELISA.
Statistical analysis
Student’s unpaired t-test was used to analyse statistical significance.
RESULTS
Characterization of cell cultures
To ensure the cultures were free from endothelial cell contamina-
tion, epithelial and stromal cultures under study were subjected to
RT-PCR for the VWF gene. VWF was strongly expressed by the
positive control endothelial cell line EAHY 926 and its identity
was confirmed by restriction mapping. However, we were unable
to detect VWF in our enriched epithelial cell populations (Figure
1) or stromal populations (data not shown). Immunostaining for
VWF was also consistently negative (data not shown; Speirs et al,
1996b).
Production of VEGF and expression of VEGF receptors
by cell cultures
All breast tumour epithelial and stromal cultures produced
VEGF. Epithelial-enriched cultures produced a mean VEGF of 33
± 7 pg ml–1 mg–1 RNA (range 11–70). Stromal cells produced
similar levels, with a mean of 48 ± 11 pg ml–1 mg–1 RNA (range
7–92). This is illustrated in Table 1. For comparison, identical
cultures were prepared from six samples of normal breast tissue
(obtained from reduction mammoplasty samples). These cultures
produced significantly lower amounts of VEGF compared with
tumour cultures (epithelial mean 19 ± 5 pg ml–1 mg–1 protein, range
9–34, P < 0.05 vs tumour epithelial culture; stromal mean 26 ± 8
pg ml–1 mg–1 protein, range 3–56). We next examined whether the
VEGF receptors, Flt-1 and KDR, were expressed by these
cultures. The Flt-1 receptor was expressed by four of six epithelial
and five of six stromal cultures (Table 1 and Figure 2). Where
present in both cell types, under semi-quantitative conditions,
Flt-1 appeared to be more abundant on stromal cells compared
with epithelial cultures. A single lobular carcinoma, BCa2, failed
to express Flt-1 on either cell type. The converse was found with
abcdefgh
Figure 1 Detection of VWF in the endothelial cell line EAHY 926 and its absence in four representative primary breast epithelial cultures. Lane a = EAHY 926,
lane b = restriction mapped product confirming product identity, lane c = negative control, lane d = 100-bp size standard, lanes e–h = primary breast epithelial
cultures. Arrow refers to product size of 509-bp, arrowheads refer to restriction digests of 300 and 209-bp
abcdefghi jklms
Figure 2 Detection of Flt-1 receptor in primary epithelial and stromal
cultures derived from breast tumours by semi-quantitative RT-PCR.
Arrowhead refers to product size of 1080-bp. Lanes a, c, e, g, i, k refer to
epithelial cultures and lanes b, d, f, h, j, l are stromal cultures. m = negative
control, s = 100-bp size standardVEGF in breast cancer 901
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KDR with constitutive expression of this receptor by epithelial
cultures and zero or reduced (3/6) expression by stromal cultures
(Table 1 and Figure 3). To determine the functionality of these
receptors, epithelial-enriched cultures were incubated with rh
VEGF (5, 10 ng ml–1) for up to 48 hours, trypsinized and counted.
However, no effects on cell proliferation were observed (data not
shown).
Effect of IL-6 and IL-8 on VEGF production in primary
breast cultures
Treatment of epithelial-enriched cultures with either IL-6 or IL-8
had no effect on VEGF production. However, when corresponding
stromal cultures were incubated with these factors, VEGF produc-
tion was decreased by up to 50%. This is illustrated in Figure 4.
DISCUSSION
This study has clearly demonstrated production of VEGF and,
unexpectedly, expression of the VEGF receptors Flt-1 and KDR
by primary cultures derived from breast tumours which were
enriched for epithelial and stromal cells. These data suggest that
VEGF and its receptors may play a significant autocrine/paracrine
role in breast tumorigenesis.
Significantly higher levels of VEGF were produced by tumour
epithelial cells compared with normal breast epithelial cells
derived from reduction mammoplasties. This is in accordance with
the increased expression of VEGF in tumour versus normal breast
reported by others (Yoshiji el al, 1996; Scott et al, 1998). This
observation suggests that VEGF may be critical for tumour growth
and invasion, and is consistent with clinical studies showing that
the degree of tumour angiogenesis is an important prognostic
factor in breast cancer (Weidner et al, 1991; Toi et al, 1993).
Similar production of VEGF165 was found for both tumour-derived
epithelial and stromal-enriched cultures, suggesting that both cell
populations may have equal importance as a source of VEGF.
Immunostaining and in situ hybridization studies have revealed
that VEGF is more commonly localized to epithelial cells (Brown
et al, 1995; Yoshiji et al, 1996). However, it has been shown that
mammary stromal cells also produce VEGF which is up-regulated
in response to hypoxia (Hlatky et al, 1994), which would be in
accord with the results presented here.
To our knowledge this is the first report of expression of Flt-1
and KDR receptors in primary cultures of epithelial and stromal
cells derived from breast tumours, although these have previously
been noted in established breast cancer cell lines (Lu and Brodie
1996). With the exception of ovarian carcinoma cells (Boocock
et al, 1995), melanoma (Gitay-Goran et al, 1993), placental
trophoblasts (Charnock-Jones et al, 1994), human testes (Ergun
et al, 1997) and monocytes which express Flt-1 but not KDR
(Hewett et al, 1996), VEGF receptors are expressed almost exclu-
sively by endothelial cells involved with tumour neovasculariza-
tion (Jakeman et al, 1992; Hewett and Murray, 1996). Because of
the nature of our cell separation prcedure combined with the high
sensitivity of the PCR technique, it was possible that we may have
been amplifying Flt-1 and KDR message from occult endothelial
cells rather than epithelial cells or fibroblasts. However, we have
previously characterized these cultures by immunocytochemistry
and flow cytometry (Speirs et al, 1998). More importantly, using
RT-PCR for the endothelial marker factor VIII, we were unable to
detect a positive signal in breast cancer cell cultures, confirming
the absence of stray endothelial cells in our epithelial and stromal
populations. The sensitivity of the PCR, in theory capable of
amplifying message from a single cell, unequivocally demon-
strates that our cultures did not contain endothelial cells. If these
were contaminants in our eniched cell populations, even at a low
level, they would have been detected by RT-PCR for factor VIII,
particularly after 35 amplification cycles.
The finding of both VEGF protein and receptors within the
same cell population suggests important autocrine/paracrine
mechanisms which may be important in direct tumour cell prolif-
eration. However, no proliferative response could be elicited when
rhVEGF was added directly to primary cultures over a 4-day
period. There are several possible explanations for this. Given that
these cultures are already producing reasonably high levels of
VEGF (as demonstrated by our ELISA results), it may be that the
receptors are already maximally stimulated and have become satu-
rated such that they would be unresponsive to exogeneous peptide.
We did not have access to a VEGF antagonist which may have
tested this hypothesis. Alternatively, VEGF receptors observed on
breast tumour cells may be involved with invasion rather than
proliferation, suggested in ovarian carcinoma which also
possesses gene transcripts for both types of VEGF receptor, but
cannot respond to exogenous rhVEGF in either paracrine or
autocrine fashion (Boocock et al, 1995). It is also possible that the
receptor gene may not be transcribed and translated to a functional
state under the in vitro conditions we describe; expression of a
functional receptor may require cell–cell or cell–matrix interac-
tions (and hence tissue integrity), which is obviously lost in vitro.
The soluble Flt-1 receptor (sFlt-1), identified in human endothelial
cells, which binds VEGF with high affinity thus preventing
VEGF-induced mitogenesis (Kendall et al, 1996) should also be
considered. One could speculate that sFlt-1 may also be produced
abcdefghi jklms
Figure 3 Detection of KDR receptor in primary epithelial and stromal
cultures derived from breast tumours by semi-quantitative RT-PCR.
Arrowhead refers to product size of 402-bp. Lanes a, c, e, g, i, k refer to
epithelial cultures and lanes b, d, f, h, j, l are stromal cultures. m = negative
control, s = 100-bp size standard
Figure 4 Effect of IL-6 and IL-8 on production of VEGF by primary breast
epithelial and stromal cultures. *P < 0.05 vs appropriate epithelial culture
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by breast primary cultures and, by binding to its ligand, may be
responsible for the lack of proliferative effect we observed when
exogenous VEGF was added to our cultures. However, a prelimi-
nary study (by sandwich ELISA) in our laboratory has failed to
demonstrate the presence of sFlt-1 in samples of conditioned
medium, although it is present in sera of some breast cancer
patients (K Heer et al, unpublished observations).
A differential expresison of Flt-1 and KDR was observed using
semi-quantitative RT-PCR, which may reflect a differential
response to VEGF by specific cell types. We observed up-regula-
tion of Flt-1 by breast stromal cells and this observation reflects
recent data from an immunostaining study where there was a trend
for Flt-1 to be associated with breast stroma rather that epithelial
cells (51% and 44% expression respectively; de Jong et al, 1998).
With KDR, the reverse was true, with very strong expression by
epithelial cells. This observation has precedent, with the differen-
tial expression of VEGF receptors having been described in
normal human testes where a paracrine mitogenic and angiogenic
role has been proposed (Ergun et al, 1997). Flt-1 has a higher
affinity for VEGF than KDR and each have different signalling
pathways (Waltenberger et al, 1994; Seetharam et al, 1995). It is
proposed that both are required to mediate the full spectrum of
VEGF binding, but the mechanisms which control VEGF signal
transduction are not fully understood.
Breast tumours express a wide range of cytokines, which are
also expressed by breast primary cultures (Speirs et al, 1996b;
Green et al, 1997). Some cytokines, in particular IL-6 and IL-8 are
up-regulated in breast tumours (Green et al, 1997). As both of
these factors are pro-angiogenic (Koch et al, 1992; Cohen et al,
1996), we examined the effect of IL-6 and IL-8 on VEGF produc-
tion by primary cultures. In breast tumour epithelial-enriched
cultures, neither IL-6 nor IL-8 affected VEGF production. This is
in contrast to the work of Cohen (1996), who demonstrated that in
tumour cell lines, expression of VEGF was induced by IL-6,
particularly in responses to hypoxia. However, none of these cell
lines were derived from breast tumours, so it is possible that cells
of different tissue origin may elicit distinct response to cytokines.
Alternatively, the response of established cell lines may differ
from that of the primary cultures used in the present study. In
stromal cultures VEGF production was reduced by up to 50% in
response to these cytokines. Down-regulation of VEGF by IL-6
and IL-8 suggests that stromal cells may be important paracrine
regulators of VEGF. In so doing they may reduce the availability
of VEGF to the surrounding neovasculature and/or epithelial cells,
possibly acting as mediators which inhibit tumour growth.
We attempted to correlate our data with available clinicopatho-
logical details. With respect to VEGF receptors, epithelial and
stromal cultures from the single lobular carcinoma available for
study failed to express Flt-1. This observation has previously been
reported and may be explained by the fact that, unlike ductal carci-
noma, in general lobular carcinoma does not induce a desmo-
plastic stromal response (Brown et al, 1995). In terms of VEGF
production, no significant difference was observed between
cultures derived from node-positive versus node-negative
tumours. However, stromal cultures derived from oestrogen
receptor-negative tumours produced more than double the amount
of VEGF produced from identical cultures derived from oestrogen
receptor-positive tumours. The significance of this observation
remains to be determined.
The findings reported here are in accord with the established
clinical importance of VEGF as an independent prognostic factor
in breast cancer (Toi et al, 1993; Linderholm et al, 1998) and
consistent with the significantly higher levels in the sera of breast
cancer patients (Dirix et al, 1997). The data presented here have
reinforced the importance of VEGF in breast cancer using an in
vitro model. More importantly, we have demonstrated non-
endothelial expression of VEGF receptors Flt-1 and KDR by
breast cancer epithelial and stromal cells. Furthermore, production
of VEGF by breast cancer stromal cells supplements a recent study
where in transgenic mice bearing oncogene-induced mammary
carcinomas, the VEGF promoter was expressed more strongly in
tumour stroma (Fukumara et al, 1998), pointing to an important
role for the stroma in VEGF production. In conclusion, these
results suggest a fundamental role for VEGF in breast cancer, not
only as an angiogenic factor, but also as an autocrine/paracrine
regulator which may facilitate tumour proliferation and subsequent
invasion.
ACKNOWLEDGEMENTS
The authors wish to thank Mr PJ Carleton, Hull Royal Infirmary,
for kindly providing us with breast tumour samples. This study
was supported by Royal Hull Hospitals NHS Trust.
REFERENCES
Adams EF, Rafferty B and White MC (1991) Interleukin-6 is secreted by breast
fibroblasts and stimulates 17b-estradiol oxidoreductase activity of MCF-7
cells: possible paracrine regulation of breast 17b-estradiol levels. Int J Cancer
49: 118–121
Boocock CA, Charnock-Jones S, Sharkey AM, McLaren J, Barker PJ, Wright KA,
Twentyman PR and Smith SK (1995) Expression of vascular endothelial
growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl
Cancer Inst 87: 506–516
Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR,
Connolly JL and Schnitt SJ (1995) Expression of vascular permeability factor
(vascular endothelial growth factor) and its receptors in breast cancer. Hum
Pathol 26: 86–91
Charnock-Jones DS, Sharkey AM, Boocock CA, Ahmed A, Plevin R, Ferrara N and
Smith SK (1994) Vascular endothelial growth factor receptor localisation and
activation in human trophoblast and choriocarcinoma cells. Biol Reprod 51:
524–530
Cohen T, Nahari D, Cerem LW, Neufeld G and Levi B-Z (1996) Interleukin-6
induces the expression of vascular endothelial growth factor. J Biol Chem 271:
736–741
Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, de Pooter C, Martin M and
van Oosterom AT (1997) Elevated levels of the angiogenic cytokines basic
fibroblast growth factor and vascular endothelial growth factor in sera of cancer
patients. Br J Cancer 76: 238–243
de Jong JS, van Diest PJ, van der Valk P and Baak JPA (1998) Expression of growth
factors, growth inhibiting factors and their receptors in invasive breast cancer.
I: An inventory in search of autocrine and paracrine loops. J Pathol 184: 44–52
de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara F and Williams LT (1992) The
fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.
Science 255: 989–991
Eppenberger U, Kueng W, Schlaeppi JM, Roesel JL, Benz C, Mueller H, Matter A,
Zuber M, Luescher K, Litschgi M, Schmitt M, Foekens JA and Eppenberger-
Castori S (1998) Markers of tumor angiogenesis and proteolysis independently
define high- and low-risk subsets of node-negative breast cancer patients.
J Clin Oncol 16: 3129–3136
Ergun S, Kilic N, Fiedler W and Mukhopadhyay AK (1997) Vascular endothelial
growth factor and its receptors in normal human testicular tissue. Mol Cell
Endocrinol 131: 9–20
Ferrara N and Davis-Smyth T (1997) The biology of vascular endothelial growth
factor. Endo Rev 18: 4–25
Folkman J (1990) What is the evidence that tumors are angiogenesis dependent?
J Natl Cancer Inst 82: 4–6
Fukamara D, Xavier R, Sugiura T, Chen Y, Park E-C, Lu N, Selig M, Nielsen G,
Taksir T, Jain RK and Seed B (1998) Tumor induction of VEGF promoter
activity in stromal cells. Cell 94: 715–725VEGF in breast cancer 903
British Journal of Cancer (1999) 80(5/6), 898–903 © Cancer Research Campaign 1999
Gitay-Goren H, Halaban R and Neufeld G (1993) Human melanoma cells but not
normal melanocytes express vascular endothelial growth factor receptors.
Biochem Biophys Res Commun 190: 702–708
Green AR, Green VL, White MC and Speirs V (1997) Expression of cytokine
messenger RNA in normal and neoplastic human breast tissue: identification of
interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer 72:
937–941
Green VL, Atkin SL, Speirs V, Jeffreys RV, Landolt AM, Mathew B, Hipkin L and
White MC (1996) Cytokine expression in human anterior pituitary adenomas.
Clin Endo 45: 179–185
Hewett PW and Murray JC (1996) Coexpression of flt-1, flt-4 and KDR in freshly
isolated and cultured human endothelial cells. Biochem Biophys Res Commun
221: 697–702
Hlatky L, Tsionou C, Hahnfeldt P and Coleman CN (1994) Mammary fibroblasts
may influence breast tumour angiogenesis via hypoxia-induced vascular
endothelial growth factor up-regulation and protein expression. Cancer Res 54:
6083–6086
Jakeman LB, Winer J, Bennett GL, Altar CA and Ferrara N (1992) Binding sites for
vascular endothelial growth factor are localised on endothelial cells in adult rat
tissues. J Clin Invest 89: 244–253
Kendall RL, Wang G and Thomas KA (1996) Identification of a soluble form of the
vascular endothelial growth factor receptor flt-1 and its heterodimerisation with
KDR. Biochem Biophys Res Commun 226: 234–328
Klagsbrun M and Soker S (1993) VEGF/VPS: the angiogenesis factor found? Curr
Biol 3: 699–702
Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG
and Strieter RM (1992) Interleukin-8 as a macrophage-derived mediator of
angiogenesis. Science 258: 1798–1801
Linderholm B, Tavelin B, Grankvist K and Henriksson R (1998) Vascular
endothelial growth factor is of high prognostic value in node-negative breast
carcinoma. J Clin Oncol 16: 3121–3128
Lu Q and Brodie A (1996) Stimulation of the growth of MCF-7 and MDA-MB-468
breast cancer cells by vascular endothelial growth factor. Proc Am Assoc
Cancer Res 37: 1499
Scott PAE, Smith K, Poulsom R, De Benedetti A, Bicknell R and Harris AL (1998)
Differential expression of vascular endothelial growth factor mRNA vs. protein
isoform expression in human breast cancer and relationship to elF-4E. Br J
Cancer 77: 2120–2128
Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S and Shibuya MA (1995)
A unique signal transduction pathway for the flt-1 tyrosine kinase receptor,
a receptor for vascular endothelial growth factor. Oncogene 10: 135–147
Speirs V, Green AR and White MC (1996a) Collagenase III: a superior enzyme for
complete disaggregation and improved viability of normal and malignant
human breast tissue. In Vitro Cell Dev Biol 32: 72–74
Speirs V, Green AR and White MC (1996b) A comparative study of cytokine gene
transcripts in normal and malignant breast tissue and primary cell cultures
derived from the same tissue samples. Int J Cancer 66: 551–556
Speirs V, Green AR, Walton DS, Kerin MJ, Carleton PJ, Fox JN, Desai SB and
Atkin SL (1998) Short-term primary culture of epithelial cells derived from
breast tumours. Br J Cancer 78: 1412–1429
Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC,
Gospodarowicz D and Bohlen P (1992) Identification of the KDR tyrosine
kinase as a receptor for vascular endothelial growth factor. Biochem Biophys
Res Commun 187: 1579–1586
Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fides JC and
Abraham JA (1991) The human gene for vascular endothelial growth factor.
Multiple protein forms are encoded through alternative exon splicing. J Biol
Chem 266: 11947–11954
Toi M, Kashitani L and Tominaga T (1993) Tumour angiogenesis is an
independent prognostic indicator in primary breast carcinoma. Int J Cancer 55:
371–374
Toi M, Kondo S, Suzuki H, Yamamoto Y, Inada K, Imazawa T, Taniguchi T and
Tominaga T (1996) Quantitative analysis of vascular endothelial growth factor
in primary breast cancer. Cancer 77: 1101–1106
Waltenberger J, Claesson-Welch L, Siegbahn A, Shibuya M and Heldin C-H (1994)
Different signal transduction properties of KDR and Flt-1, two receptors for
vascular endothelial growth factor. J Biol Chem 269: 26988–26955
Yoshiji H, Gomez DE, Shibuya M and Thorgeirsson UP (1996) Expression of
vascular endothelial growth factor, its receptor, and other angiogenic factors in
human breast cancer. Cancer Res 56: 2013–2016
Weidner N, Semple JP, Welch WR and Folkman J (1991) Tumour angiogenesis and
metastasis: correlation in invasive breast cancer. N Engl J Med 324: 1–8